Study the impact of diabetes outcomes with covid 19 in Rewa

https://doi.org/10.54037/WJPS.2022.100115

Authors

  • Dr. Shivani Awasthi Department of Biochemistry, A.P.S.U., Rewa, (M.P.) India

Keywords:

diabetes, morbidity, mild, moderate, severe, co-morbidity, cerebrovascular, glycemic control, acute respiratory

Abstract

Eighteen months into the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) (corona virus disease 2019 [COVID-19]) pandemic, epidemiologic studies show that diabetes is a vital contributor to severe COVID-19 morbidity, and, conversely, COVID-19 has had a devastating effect on the population with diabetes. Most cases that have been admitted have been mild to moderate since the early stages of the outbreak. However, there has been an enhance in the number of severe cases and deaths as a outcome of COVID-19, which creates it imperative to evaluate the risk factors for progression of the disease. Current evidence from China and the US recommends that co- morbidities such as hypertension, diabetes, obesity, chronic obstructive pulmonary disease (COPD) and cerebro-vascular disease increase the risk of severity and death from COVID-19. However, there are significant differences in demographic patterns and disease trends between high-income and low- and middle-income countries. COVID-19 infection disrupts glucose regulation, rendering glycemic control difficult and necessitating particularly careful management in patients with diabetes.

Downloads

Published

2022-01-02

How to Cite

Dr. Shivani Awasthi. (2022). Study the impact of diabetes outcomes with covid 19 in Rewa: https://doi.org/10.54037/WJPS.2022.100115. World Journal of Pharmaceutical Sciences, 10(01), 136–143. Retrieved from http://wjpsonline.com/index.php/wjps/article/view/study-impact-diabetes-outcomes-covid-rewa

Issue

Section

Research Article